Biomedical International R + D Gmbh

Other

Medigene Ag

Biomay Produktions-und Handels Ag

Bio Life Science Forschungs - Und Entwicklungsgesellschaft Mbh

Bio Life Science Forschungs- Und Entwicklungsges.m.b.h.

Erika Jensen-Jarolim

Franziska Roth-Walter

Otto Scheiner

Heimo Breiteneder

Christoph Zielinski

Luis Fernandez Pacios

Cristina Gomez-Casado

Josef Singer

Araceli Diaz Perales

Uwe Michaelis

Hubert Pehamberger

Ursula Wiedermann

Margit Weghofer

Christoph Rehfuess

Ingo Flaschberger

Franz Gabor

Hubert Penamberger

Franziska Walter

Prof Dr Ursula-Wiedermann Ursula-Wiedermann

Disclosed is a method for diagnosing allergy in a human or animal patient, wherein the level of species-specific lipocalin, especially lipocalin 2 in a human patient, is measured in a sample of said patient and wherein a lowered level of said lipocalin compared to the level of said lipocalin in the corresponding sample of a human or animal that has no allergy, is indicative of an allergy, as well as a kit for performing this method, and a kit for quality control of allergen molecules or extracts used for immunotherapy of allergy by determining its siderophore-iron ligand load and thus immunomodulatory potency. Further, lipocalin proteins for use in treatment or prevention of allergies are provided, preferably complexed with siderophore-iron ligands.

Method and means for diagnosing and treating allergy

The present invention relates to parvovirus mutated structural proteins comprising insertions of mimotopes of a HER2, compositions, multimeric structures, medicaments and vaccines comprising the same, nucleic acids, expression cassettes, constructs, vectors and cells comprising the nucleic acids, methods of preparing the structural proteins and methods of inducing a B-cell response or of treating a HER2-related disease.

Anti-HER2 vaccine based upon AAV derived multimeric structures

A method for an observational screening method or a drug screening method, includes the steps of providing an enclosure for at least one animal with outer sidewalls, preferably 4 outer sidewalls; providing temperature sensing device for sensing a body temperature of at least one animal and/or activity measurement device for measuring at least one parameter related to physical activity of at least one animal; sensing a body temperature of at least one animal and/or measuring at least one parameter related to physical activity of at least one animal; providing data processing device; and processing data related to body temperature and/or to the parameter related to physical activity.

Non-invasive temperature and physical activity measurement of animals

Microspheres containing antigens for allergy therapy, the microspheres having a binding constant of 1&#xd7;10Mtoward a specific carbohydrate residue of intestinal and/or nasal epithelial cells.

Antigen-containing microspheres for the treatment of allergies

The present invention relates to peptides of the extracellular domain of a HER-2/neu protein, conjugates comprising said peptides linked to an immunogenic carrier, compositions thereof, nucleic acid molecules, vectors and transformed or transfected host cells comprising said nucleic acid molecules encoding said peptides or conjugates, and methods for producing the disclosed peptides, conjugates and compositions. The present invention also relates to diagnostic methods of detecting cancerous conditions associated with HER-2/neu or monitoring the effectiveness of treatment against cancerous conditions associated with HER-2/neu. The present invention also relates to methods of eliciting or enhancing an immune response to HER-2/neu in a subject in need thereof.

Vaccine against cancer diseases that are associated with the her-2/neu oncogene

The present invention provides a method for producing a vaccine against cancerous disease, and the vaccine itself. This method involves first using one or more antibodies that are specifically effective against one or more antigens specially expressed by the tumor cells to select one or more mimotopes of said antigens from a phage peptide library. To obtain the vaccine, said mimotopes are conjugated to a macromolecular carrier singly or multiply in the form of their mono-, di-, tri- or oligomers. When administered, the inventively produced vaccine leads to a humoral immune response and thus to the formation of an active immunity as a consequence of vaccination.

Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells

Growing community of inventors

Vienna, Austria

Erika Jensen-Jarolim